Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tourmaline Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TRML
Nasdaq
8731
https://www.tourmalinebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tourmaline Bio Inc
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Apr 2nd, 2024 11:00 am
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Mar 19th, 2024 11:00 am
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
- Mar 1st, 2024 11:05 am
Tourmaline Bio to Present at Upcoming Investor Conferences
- Feb 27th, 2024 12:30 pm
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Feb 1st, 2024 1:00 pm
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Jan 29th, 2024 9:01 pm
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
- Jan 25th, 2024 12:00 pm
Tourmaline Bio Announces Proposed Public Offering of Common Stock
- Jan 24th, 2024 9:05 pm
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
- Jan 8th, 2024 12:00 pm
Tourmaline Bio added to the NASDAQ Biotechnology Index
- Dec 15th, 2023 9:00 pm
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
- Dec 14th, 2023 12:30 pm
CEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio Inc
- Oct 27th, 2023 1:02 am
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
- Oct 19th, 2023 9:37 pm
Scroll